This was a phase 1 trial to determine the recommended phase 2 dose, safety and efficacy of oxaliplatin followed by irinotecan and capecitabine given every 3 weeks as a triple combination (IXO regimen) in patients with unresectable mCRC. IXO administered every 3 weeks as first-line therapy for mCRC is active by improving response rate and survival. Background: The objective of the present phase I study was to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of irinotecan, capecitabine, and oxaliplatin given in combination (IXO regimen) to patients with previously untreated, unresectable advanced or metastatic colorectal cancer (CRC). Patients and Methods: Patients received oxaliplatin followed by irinotecan as intravenous infusions on day 1, with oral capecitabine taken twice daily (BID) on days 2 to 15 of a 3-week cycle. The dose ranges were explored as follows: oxaliplatin, 75 to 120 mg/m The median progression-free survival was 11 months, and the median overall survival was 25 months. The survival rate at 5 years was 23%. Conclusion: The IXO regimen has a manageable toxicity profile with promising antitumor activity as first-line treatment of advanced and metastatic CRC.
Introduction
Although the prognosis is poor for patients with unresectable metastatic colorectal cancer (mCRC), 1 no new cytotoxic drugs have been developed or approved since the early 2000s. New treatment strategies need to be explored. Improved outcomes have been obtained by combining and sequencing existing chemotherapeutic agents. The Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) study 2 demonstrated improved overall survival (OS) of patients with mCRC by combining 2 cytotoxic agents. Furthermore, a meta-analysis of phase III trials concluded that combination therapy should be the standard of care for first-line treatment of patients with advanced CRC. 3, 4 These findings have led to increased interest in triple combinations with irinotecan, oxaliplatin, and fluoropyrimidines, supported by in vitro data that showed that previous incubation of human colon cancer cell lines with oxaliplatin increased irinotecan cytotoxicity. 5 Two phase III studies comparing a triplet combination regimen, FOLFOXIRI (irinotecan, oxaliplatin, 5-fluorouracil [5-FU]/leucovorin), against a doublet, FOLFIRI (5-FU, leucovorin, irinotecan), as first-line therapy for patients with mCRC have reported conflicting results. 6, 7 The GONO (Gruppo Oncologico Nord Ovest) trial reported improvements in the response rate, progression-free survival (PFS), OS, and secondary resection rate with the FOLFOXIRI regimen. 6 However, the Hellenic Oncology
Research Group study, 7 The main objective of the present study was to determine the safety of oxaliplatin, followed by irinotecan and capecitabine (Xeloda), given every 3 weeks as a triple combination (IXO regimen) in patients with unresectable mCRC. The secondary objective included assessment of the efficacy of this particular regimen.
Patients and Methods

Study Design
A phase I, single-arm, open-label study was conducted at The Ottawa Hospital Cancer Centre (available at: www. canadiancancertrials.ca; protocol identification no. OCT1162). The Ottawa Hospital research ethics board approved the present study, which was performed in accordance with the provisions of the Declaration of Helsinki, International Conference on Harmonisation, and Good Clinical Practice guidelines. The patients were informed of the study and provided written informed consent before enrollment. The CONSORT checklist is provided as supporting information in Supplemental Figure 1 (in the online version).
Patients
Eligible patients were aged ! 18 years and had an Eastern Cooperative Oncology Group performance status of 2, measurable disease using the Response Evaluation Criteria in Solid Tumors, version 1.0, 8 and histologically documented locally advanced CRC or mCRC, which had been evaluated as unresectable. The surgical unresectability was established through a multidisciplinary evaluation, performed by medical and radiation oncologists and colorectal and hepatobiliary surgeons. No previous chemotherapy for advanced disease was allowed. Previous adjuvant therapy with fluoropyrimidines, but not irinotecan or oxaliplatin, was permitted. Adequate hematologic, renal, and hepatic function was required.
Treatment and Dose-escalation Protocol
We performed a phase I trial with a standard 3-to 6-patient cohort design. 9 All patients received the IXO regimen. The 3-week IXO cycle was based on the recommended capecitabine monotherapy oral administration of 2 tablets twice daily (BID) for 2 weeks, followed by a 1-week rest period. Each cycle consisted of oxaliplatin given as a 2-hour intravenous infusion, followed by a 60-to 90-minute intravenous infusion of irinotecan on day 1, with oral capecitabine BID given on days 2 to 15, every 3 weeks. of the dosage increments during dose escalation were considered independently for each drug, according to the type and severity of toxicity encountered in the previous cohort. Dose escalation was allowed between patient cohorts but not within individual patients. The maximum tolerated dose (MTD) was defined as the highest dose level (DL) at which 33% of patients experienced a dose-limiting toxicity (DLT); the MTD was recommended for further phase II evaluation. 10 With the occurrence of IXO-related toxicities, dose reductions were recommended before treatment delays. The dose adjustments were consistent with the individual package labels. Treatment continuation required recovery to toxicity grade 1. Once a drug dose had been reduced for a patient, no dose re-escalation was permitted. Treatment was discontinued in the case of serious or unmanageable toxicity, by patient request, or by physician decision. Otherwise, therapy was continued until the development of progressive disease using the Response Evaluation Criteria in Solid Tumors, version 1. 8 
Toxicity, DLT, and Tumor Response Evaluations
Screening included clinical history, physical examination, full blood count, biochemistry panel, urinalysis, and creatinine clearance (calculated using serum creatinine). Toxicity and laboratory test results were assessed on day 1 of every treatment cycle. Hematology was assessed weekly. Adverse events were evaluated continuously from the start of study treatment until 30 days after the final dose of study treatment. Toxicities were graded using the National Cancer Institute Common Toxicity Criteria, version 2.0.
11
The DLT evaluation period was limited to the first cycle (3 weeks) of treatment. Hematologic DLTs were defined as an absolute neutrophil count <0.5 Â 10 9 /L for ! 7 days, febrile neutropenia (absolute neutrophil count < 1.0 Â 10 9 /L, fever ! 38.5 C), platelet
/L, and grade 3 thrombocytopenic bleeding. Nonhematologic DLTs were defined as any grade 3/4 event (excluding alopecia, nausea, vomiting, and transient transaminase elevations), creatinine clearance < 40 mL/min, and grade ! 2 neurotoxicity for > 5 days.
The tumor response was evaluated using computed tomography at baseline and every 6 weeks (every 2 IXO cycles) thereafter until disease progression. Evaluable patients should have received ! 1 cycle of chemotherapy and had their disease reevaluated after study treatment. After discontinuation of IXO, patients were assessed every 3 months until disease progression.
Clinical antitumor activity was measured using the investigatorassessed objective response rate (ORR), PFS, and OS. Responses were confirmed ! 6 weeks after the initial computed tomography scan had documented the reduction. The duration of response was measured from the first documentation of a complete or partial response until the first documentation of progressive disease or death, whichever occurred first. PFS was defined as the interval from enrollment until disease progression or death from any cause. OS was defined as the interval from the day of enrollment until death.
Statistical Analysis
The present clinical trial was not powered for inferential statistical analyses. Continuous variables were summarized using the median and range. Categorical variables were summarized with numbers and percentages. Waterfall plots were used to illustrate the tumor response. ORRs are reported with 95% confidence intervals (CIs). The median PFS and OS were obtained from the 50th percentile of the estimated Kaplan-Meier survival rates and are presented with the 95% CIs.
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Results
Patient Characteristics
The baseline characteristics of the 39 patients enrolled are presented in Table 1 . The CONSORT flow diagram is provided as supporting information in Supplemental Figure 2 (in the online version). One patient, who had been enrolled in error while the study was on hold for resolution of drug source issues, was notified and then agreed to continue in the study. Patients discontinued study treatment for the following reasons: disease progression (n ¼ 16); toxicity (neutropenia, n ¼ 2; recurring grade 2/3 toxicity, n ¼ 1); death (n ¼ 2; 1 unrelated to treatment); complete response (n ¼ 3); patient's best interest (liver resection, n ¼ 10; patient request after prolonged treatment, n ¼ 3; clinical deterioration, n ¼ 1; and scheduled heart surgery, n ¼ 1).
Treatment Exposure
Overall, patients received 466 cycles. The median was 11 cycles per patient (range, 1-34). Six patients (15%) received > 20 cycles. The mean dose intensity was 85% for oxaliplatin, 90% for irinotecan, and 85% for capecitabine.
Of the 39 patients, 24 (61%) required ! 1 dose reduction after a median of 3 cycles (range, 1-13 cycles) because of toxicity (diarrhea and neutropenia). Also, 25 patients (64%) required ! 1 dose delay after a median of 4 cycles (range, 1-17 cycles) because of toxicity (neutropenia and diarrhea) and patient request. For 18 patients (46%), the IXO schedule was changed from a 3-to a 4-week schedule after a median of 7 cycles (range, 1-18 cycles), mostly because of delays for neutropenia and diarrhea. The patients who had undergone liver resection (n ¼ 10; 26%) had received a median of 13 preoperative cycles (range, 4-31 cycles) and 3 postoperative cycles (range, 1-4 cycles). In addition, 23 patients (59%) received further lines of antineoplastic treatment.
Dose Escalation
The dose-escalation steps, DLTs, and serious adverse events are summarized in Table 2 . The first patient at DL1 experienced a DLT (febrile neutropenia with bowel perforation at the site of an unresected primary tumor). We assessed DL1 as not tolerated, and all drug doses were reduced by 10%. At DL2 (the new starting point for the dose escalations), 1 DLT of grade 3 diarrhea occurred. At DL3, febrile neutropenia was documented in 1 patient. At DL4, 1 patient experienced febrile neutropenia in cycles 2 and 3; the doses were not reduced for cycle 3, and the patient died of septic shock and aspiration. One patient died of a sudden stroke, which was considered unrelated to treatment. No DLT occurred at DL5 or DL6. At DL7, 1 patient experienced grade 3 dehydration. At DL8, the acceptable toxicity was exceeded, with 2 patients experiencing the same DLT of grade 3 diarrhea.
In summary, the DLTs were grade 3 diarrhea (n ¼ 3), febrile neutropenia (n ¼ 3), and grade 3 dehydration (n ¼ 1). The MTD and recommended phase II dose (RP2D) were oxaliplatin 100 mg/ m 2 , irinotecan 160 mg/m 2 , and capecitabine 950 mg/m 2 BID. At the RP2D, diarrhea and neutropenia were the main toxicities (grade ! 2).
Safety and Tolerability
Treatment-related toxicities and the proportion of patients experiencing grade 1/2 and grade 3/4 events are shown in Table 3 and Figure 1 , respectively. Of the 39 patients, 24 (61%) experienced ! 1 grade 3/4 toxic event.
During dose escalation, the most commonly occurring hematologic adverse events were neutropenia (n ¼ 37; 95%), anemia (n ¼ 34; 87%), and thrombocytopenia (n ¼ 30; 77%; Table 3 ). Although thrombocytopenia and anemia were generally grade 1 or 2 in severity, neutropenia tended to be of grade 2 or 3, with grade 4 events documented in 8 patients (21%).
The most common nonhematologic events were nausea or vomiting (n ¼ 36; 92%), followed by neurosensory events (n ¼ 34; 87%), diarrhea (n ¼ 33; 85%), and fatigue (n ¼ 30; 77%; Table 3 ). Most events were of grade 1 or 2 in severity ( Figure 1 ). Grade 4 events were observed in only 2 patients (5%) and was febrile neutropenia in both cases. Grade 2/3 diarrhea appeared to be related to the irinotecan and capecitabine doses. Most neurosensory events were grade 1 severity with only 3 grade 2 events (8%) and 1 grade 3 event (3%), despite the high number of oxaliplatin cycles administered. At the RP2D, 5 of 6 patients experienced grade 3 toxicities; however, no grade 4 toxicities were observed. Of the 14 serious adverse events reported in 12 patients (31%), most (57%) were experienced by the 6 patients enrolled at the dose level that exceeded the recommended dose (Table 2) . Two patients died while receiving 
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Efficacy
Thirty-eight patients were evaluable for response. One patient had died of a stroke before the first response evaluation. The ORR was 77% (95% CI, 63%-91%), with 6 complete responses (2 unconfirmed) and 24 partial responses (2 unconfirmed). A waterfall plot of the best tumor response is shown in Figure 2A .
The responses were achieved rapidly and observed after only 2 cycles of treatment, with confirmation or stabilization after 4 to 6 cycles ( Figure 2B-D) . The median time to the first response was 5.1 weeks. The median duration of response was 10.5 months (95% CI, 9-12 months). The disease control rate (overall response and stable disease) was 90% (95% CI, 80%-100%). Ten patients (26%) underwent curative-intent surgery for metastases. The median PFS was 11 months (95% CI, 9-15 months; Figure 3A) . After a median follow-up of 71 months (range, 1-81 months), 30 patients had died and 9 were alive. The median OS was 25 months (95% CI, 18-36 months; Figure 3B ). The 3-and 5-year survival rates were 33% and 23%, respectively.
Discussion
The current treatment of patients with mCRC is the combination of 2 cytotoxic drugs. 12, 13 However, exposure to the 3 available cytotoxic agents, fluoropyrimidines, oxaliplatin, and irinotecan, has provided even better outcomes. The FOLFOXIRI triple combination, associated in a phase III study with greater survival rates, improved PFS, better responses, and a greater magnitude of responses, 6 has been recommended in National Comprehensive Cancer Network guidelines as level 2B evidence for the treatment of mCRC. Since our IXO study began in 2004, with the last closeout visits occurring in 2007, the therapeutic options have improved with addition of systemic biologic targeted agents, although no complementary or alternative treatments have yet been found to be effective in colon cancer. Moreover, the dose intensity and dose schedule of the triplet chemotherapy-based regimens have continued to be investigated for the first-line treatment of patients with mCRC. 14 We believe that our research contributes to the better understanding of the possible therapeutic opportunities and the limitations and optimization of triplet chemotherapy regimens for patients with mCRC.
To the best of our knowledge, our IXO study has explored for the first time a 3-week schedule of the combination of irinotecan, capecitabine, and oxaliplatin. Previously reported studies of this triple combination had investigated either 2-week [15] [16] [17] [18] [19] [20] or 5-week 21 schedules. Our study has outlined the safety profile of the IXO regimen for patients with mCRC. The RP2D of the IXO regimen was irinotecan 160 mg/m 2 and oxaliplatin 100 mg/m 2 on day 1 every 3 weeks and capecitabine 950 mg/m 2 BID starting on day 2 for 14 days. Diarrhea and febrile neutropenia were the main DLTs, consistent with other triple combination studies of irinotecan, oxaliplatin, and fluoropyrimidines, including capecitabine, 15, 19 5-FU, 22, 23 and S-1. 24 We continued to observe DLT-like toxicity after the first cycle, supporting the recommendation of Postel-Vinay et al 25 to continue monitoring diligently for late severe toxicities after the RP2D had been defined. b One patient developed short-term neutropenia that was not considered a DLT. c Late onset defined as toxicity beginning > 24 hours after administration of irinotecan. d One patient experienced grade 3 fatigue for 30 minutes on day 1 that was evaluated by the treating physician and the primary investigator, and subsequently by the study monitoring committee, with the conclusion that it was not a DLT; however, at the treating physician's discretion, doses were reduced for cycle 2 as a protocol deviation. e One of the cases of febrile neutropenia resulted in the death of the patient. Grade 3/4 toxicities were observed in 61% of patients; most of them occurred at the dose level above the RP2D. The most common grade 3/4 toxicity was neutropenia, which was encountered within the first 3 cycles. Neutropenia was the only grade 4 event reported in our study, and 1 patient died as a result of treatment-related febrile neutropenia identified after the third cycle. Diarrhea, the most common dose-limiting nonhematologic event, was of grade 2/3 severity. All other toxicities associated with the IXO regimen were of mild to moderate severity. Despite the large number of cycles received, a lower than expected frequency of grade 3/4 oxaliplatin-associated neurotoxicity had occurred, which could be accounted for by the reduced dose intensity associated with a 3-week schedule and/or a switch from a 3-to 4-week schedule. The febrile neutropenic event in the first patient enrolled in the study at DL1 and the pattern of the rate of increase of grade 3/4 diarrhea and neutropenia, suggest that in our triple combination, the escalation of irinotecan increased these toxicities. The safety of IXO in our phase I study was manageable, comparable to that of XELOXIRI (capecitabine, oxaliplatin, irinotecan), 15 COI (capecitabine, oxaliplatin, irinotecan), 18 FOL-FOXIRI, 6 or TIROX (S-1, irinotecan, oxaliplatin), 24 achieved through the use of ongoing monitoring and initiation of appropriate therapeutic and/or supportive care measures. Consistent with other triple combinations in different tumors, [26] [27] [28] careful selection of patients with good performance status and ongoing patient monitoring is warranted.
In the present IXO trial, the confirmed response rate was 67% (the unconfirmed response rate was 77%), with disease control achieved in nearly all patients (90%). The response to the IXO regimen was rapid, attained after 2 cycles of treatment. Significant tumor downsizing was observed during the first 6 cycles, after which the responses appeared to be maintained. The median PFS was 11 months. Our results are within the range of values reported by other phase I/II studies of 2-week IXO in terms of ORR and PFS. 15, 16, 19, 21 Despite the limitations, our data from a phase I trial are also consistent with the results from first-line randomized controlled studies of FOLFOXIRI. Of the 39 patients with unresectable advanced CRC enrolled in our study, treatment with the IXO regimen led to a median PFS of 11 months and median OS of 25 months. FOLFOXIRI in phase III trials 6, 7 led to a median PFS of 8 to 10 months and median OS of 22 to 23 months. IXO was also associated with a high response rate of 67%; phase III trials of FOLFOXIRI have reported a 43% to 66% response rate. Thus, IXO use resulted in a 28% resectability rate and a favorable R0 resection rate of 18%; the R0 resection rate with FOLFOXIRI in phase III trials was 15%. 6, 7 This is an important outcome from our study, because the long-term follow-up data have shown that patients who undergo radical resection will have prolonged survival, with a 5-and 8-year survival rate of 42% and 33%, respectively. 26 However, 1 limitation of our study was the small number of patients with favorable predictive characteristics (ie, 95% patients had an Eastern Cooperative Oncology Group performance status of 
In this context, the IXO regimen can be distinguished from 5-FUebased triple combination regimens (eg, FOLFOXIRI) by its relative simplicity. The IXO regimen eliminates the need for venous access and continuous 5-FU infusion, which could be more desirable for many eligible patients, and reduces the administration costs. Moreover, in contrast to the regimens delivered biweekly, such as FOLFOXIRI, IXO given every 3 weeks appeared to be associated with a lower frequency of oxaliplatin-associated neurotoxicity.
The realization has been increasing that the triple combination will benefit patients with gastrointestinal tumors. Further evaluations have been conducted in patients with mCRC in combinations with bevacizumab, 29, 30 neoadjuvant rectal cancer (unpublished data), or metastatic gastric cancer.
31,32
Conclusion IXO administered every 3 weeks as first-line therapy for mCRC is highly active by improving the response rate and survival. However, this results in increased toxicity, including neurotoxicity and neutropenia. However, the toxicity was manageable through dose adjustments. Switching from a 3-to 4-week schedule also improved the regimen's tolerability. Therefore, IXO can be recommended for physically fit patients with a preference and support system for aggressive triplet chemotherapy, including patients without access or with difficult access to the chemotherapy port and infusion pump management services, and for whom oral administration of capecitabine is a convenient substitute for infused 5-FU. The speed and magnitude of downsizing of metastatic lesions would deem IXO of interest for converting borderline unresectable metastatic disease to resectable status. Good results in tumor shrinkage could support the use of IXO in the neoadjuvant treatment of primary rectal cancer. Additional prospective clinical trials are warranted to better examine the role of scheduling in the activity and tolerability of the triplet combination and to identify the potential of IXO within this population.
Clinical Practice Points
We have described a phase I study that investigated the safety and efficacy of the IXO regimen, a 3-week triple combination of capecitabine, oxaliplatin, and irinotecan, as first-line treatment of patients with advanced CRC. To the best of our knowledge, this is the first study to investigate a 3-week schedule; previous studies of this triple combination tested 2-or 5-week schedules. We have described the safety of the IXO regimen and the DLTs, MTDs, and the recommended doses for phase II study. We have reported the full details of the toxicities that occurred at each dose level and our experience in mitigating these toxicities. We have described the efficacy findings, in terms of the response rates, PFS, and OS. We propose continuing the investigation of the IXO regimen for maintenance therapy for advanced CRC, conversion of borderline unresectable mCRC, and neoadjuvant downsizing of rectal cancer. Our findings suggest that IXO can improve survival beyond that of first-line treatment doublet regimens in fit patients with mCRC and increase the resectability rate for patients with borderline unresectable disease. 
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